empest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure

-Encouraging preliminary clinical responses support option exercise, results planned for presentation at a major scientific conference

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.